Study #2023-0156
EVEREST-1: A phase 1/2 study to evaluate the safety and efficacy of A2B530, an autologous logic-gated Tmod chimeric antigen receptor T Cell (CAR T), in heterozygous HLA-A*02 adult subjects with recurrent unresectable, locally advanced, or metastatic solid tumors that express CEA and have lost HLA-A*02 expression.
MD Anderson Study Status
Enrolling
Treatment Agent
A2B530, Diagnostic Test: xT-Onco with HLA-LOH Assay
Description
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that express CEA and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the maximum or recommended dose of A2B530 that is safe for patients * Phase 2: Does the recommended dose of A2B530 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: * Enrollment and Apheresis in BASECAMP-1 (NCT04981119) * Preconditioning Lymphodepletion (PCLD) Regimen * A2B530 Tmod CAR T cells at the assigned dose
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
Study phase:
Physician name:
Maria Pia Morelli
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-866-478-2259
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.